Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Establishment of InMotion, an independent, fee-free community center for persons with movement disorders
Objective: To describe the establishment of a community center, InMotion (IM), for persons with movement disorders. Background: Needs of people with movement disorders grow with…When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis
Objective: To quantify the number of turning in bed throughout the night as a determinant of the severity of nocturnal hypokinesia. Background: Nocturnal hypokinesia or…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Distribution of oscillatory activities in MRI confirmed subthalamic nucleus subregions
Objective: To explore the differences and similarities of oscillatory activity between subregions of the subthalamic nucleus (STN). Background: In Parkinson's disease (PD), treatment driven changes…Stimulation of the globus pallidus internus in the treatment of Parkinson’s disease: Long-term results of a monocentric follow-up
Objective: To investigate the long-term outcome of pallidal deep brain stimulation (GPi-DBS) in Parkinson's disease (PD). Background: GPi-DBS is beneficial in patients with advanced levodopa-responsive…The effect of short pulse width neurostimulation in GPi-DBS
Objective: To evaluate (1) clinical usefulness and (2) adverse effects of thirty microseconds pulse width stimulation in deep brain stimulation of the globus pallidus internus…Variability in the ideal target of GPi DBS for Parkinson’s disease requires advanced direct targeting for optimal results
Objective: Our findings have the potential to transform the clinical practice of surgeons who rely solely on indirect targeting, by raising awareness of the anatomic…Could tonic chin electromyogram density be a potential marker for differentiating atypical Parkinsonian syndromes from Parkinson’s disease among alpha-synucleinopathies?
Objective: The study aimed to examine whether the video-polysomnography (vPSG) could provide some clues for differentiating atypical Parkinsonian syndromes (APS) from Parkinson's disease (PD) among…
- « Previous Page
- 1
- …
- 347
- 348
- 349
- 350
- 351
- …
- 388
- Next Page »